動作緩慢の世界市場レポート 2025年

動作緩慢の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.4％で56億4,000万米ドルに成長します。予測期間の成長は、世界のパーキンソン病有病率の上昇、神経疾患の発生率の増加、神経変性疾患に罹患しやすい高齢化、動作緩慢の認知度向上と早期発見、新興市場における診断能力の強化などに起因すると考えられます。この期間に予想される主要動向としては、神経刺激技術の発展、革新的なドラッグデリバリーシステムの出現、動作追跡や症状モニタリングのためのウェアラブルデバイスの採用、遠隔医療や神経学遠隔診察の拡大、運動機能障害の治療を目的とした遺伝子治療の開発などが挙げられます。

神経疾患の有病率の上昇は、今後数年間の動作緩慢市場の成長を牽引すると予想されます。これらの疾患は、脳、脊髄、末梢神経に影響を及ぼし、運動、感覚、認知、その他の身体機能に障害をもたらす病状です。神経疾患の世界の増加は、人口の高齢化が主要原因であり、加齢に伴う脳の変化が神経系疾患のリスクを高めるからです。神経疾患の多くは動きの鈍化や低下と関連しているため、動作緩慢を含む運動機能障害に対処する治療に対する需要が高まっています。例えば、2023年1月、米国を拠点とする擁護団体である米国パーキンソン病協会（APDA）は、パーキンソン病は2030年までに130万人が罹患すると予想され、診断された症例の一貫した増加を反映していると報告しました。したがって、神経疾患の罹患率の増加は、動作緩慢市場の拡大に大きく貢献することになります。

動作緩慢市場の主要企業は、錠剤を飲み込むのに苦労している患者に、より簡単な投与を提供するために、舌下療法などの革新的なソリューションの開発を優先しています。舌下療法では、舌の下に薬剤を置くことで、粘膜を通して血流に素早く吸収され、迅速な治療効果を得ることができます。例えば、2023年3月、ポルトガルに本社を置くパーキンソン病治療を専門とするBIALは、パーキンソン病のOFFエピソードをオンデマンドで管理するためのKYNMOBI（アポモルヒネ塩酸塩）を発表しました。このOFFエピソードは、標準的な薬剤が効かなくなったときに、動作緩慢、振戦、硬直などの症状が再発または悪化することを特徴とします。アポモルヒネ塩酸塩の舌下フィルム製剤は、舌の下で溶けるため即効性があり、使いやすい選択肢となります。非エルゴリン系ドパミンアゴニストとして、急激な運動変動への対処を助け、一般的に忍容性が高く、休薬期間中により一貫した症状のコントロールを記載しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の動作緩慢：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の動作緩慢市場：成長率分析
• 世界の動作緩慢市場の実績：規模と成長、2019～2024年
• 世界の動作緩慢市場の予測：規模と成長、2024～2029年、2034年
• 世界の動作緩慢：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の動作緩慢市場、併用療法別、実績と予測、2019～2024年、2024～2029年、2034年
• 単剤療法
• 併用療法
• 世界の動作緩慢市場、病気重症度別、実績と予測、2019～2024年、2024～2029年、2034年
• パーキンソン病の初期段階
• 進行期パーキンソン病
• 世界の動作緩慢市場、症状管理別、実績と予測、2019～2024年、2024～2029年、2034年
• 動作緩慢
• 震え
• こわばり
• 世界の動作緩慢市場、単剤療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• レボドパ
• ドーパミン作動薬
• MAO-B阻害剤
• 抗コリン薬
• アマンタジン
• 世界の動作緩慢市場、併用療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• レボドパとカルビドパ
• レボドパとCOMT阻害剤
• ドーパミン作動薬とMAO-B阻害剤
• レボドパとMAO-B阻害剤
• トリプルセラピー

第7章 地域別・国別分析

• 世界の動作緩慢市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の動作緩慢市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 動作緩慢市場：競合情勢
• 動作緩慢市場：企業プロファイル
  • AbbVie Inc.
  • Novartis AG
  • Medtronic Plc
  • Eli Lilly and Company
  • Otsuka Pharmaceutical Co. Ltd.

第31章 その他の大手企業と革新的企業

• Biogen Inc.
• Eisai Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Lundbeck AS
• Amneal Pharmaceuticals Inc.
• Orion Corporation
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics Inc.
• Denali Therapeutics Inc.
• Adamas Pharmaceuticals
• Impel NeuroPharma
• Annovis Bio Inc.
• BlueRock Therapeutics LLC
• NeuroDerm Ltd.
• Cerevance LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 動作緩慢市場、2029年：新たな機会を提供する国
• 動作緩慢市場、2029年：新たな機会を提供するセグメント
• 動作緩慢市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Bradykinesia is characterized by a distinct slowness in starting and carrying out voluntary movements. It commonly appears as a decreased ability to perform quick, alternating motions or trouble completing everyday tasks that require motor coordination. Affected individuals may seem less spontaneous in their movements, with activities like walking, writing, or displaying facial expressions becoming noticeably slower.

The primary treatment approaches for bradykinesia include monotherapy and combination therapy. Monotherapy involves the administration of a single drug, most often a dopamine replacement or agonist, aimed at alleviating symptoms related to slowed movement. It is applied in both early and advanced stages of Parkinson's disease to manage symptoms such as bradykinesia, tremors, and muscle rigidity.

The bradykinesia market research report is one of a series of new reports from The Business Research Company that provides bradykinesia market statistics, including bradykinesia industry global market size, regional shares, competitors with a bradykinesia market share, detailed bradykinesia market segments, market trends and opportunities, and any further data you may need to thrive in the bradykinesia industry. This bradykinesia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bradykinesia market size has grown rapidly in recent years. It will grow from $3.00 billion in 2024 to $3.41 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth during the historical period can be attributed to the rising number of movement disorder clinics, the increasing burden of post-stroke motor complications, the prevalence of hereditary neurodegenerative diseases, a surge in clinical trials focused on bradykinesia-related treatments, and the expansion of healthcare infrastructure.

The bradykinesia market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The projected growth in the forecast period can be attributed to the global rise in Parkinson's disease prevalence, a growing incidence of neurological disorders, an aging population susceptible to neurodegenerative conditions, increased awareness and early detection of bradykinesia, and the enhancement of diagnostic capabilities in emerging markets. Key trends expected during this period include advancements in neurostimulation technologies, the emergence of innovative drug delivery systems, the adoption of wearable devices for motion tracking and symptom monitoring, the expansion of telehealth and remote neurology consultations, and the development of gene therapies aimed at treating motor dysfunction.

The rising prevalence of neurological disorders is expected to drive the growth of the bradykinesia market in the coming years. These disorders are medical conditions that impact the brain, spinal cord, or peripheral nerves, resulting in impairments in movement, sensation, cognition, or other bodily functions. The global increase in neurological disorders is largely attributed to an aging population, as age-related changes in the brain heighten the risk of nervous system diseases. As many neurological conditions are associated with slowed or reduced movement, there is a growing demand for treatments that address motor dysfunction, including bradykinesia. For example, in January 2023, the American Parkinson Disease Association (APDA), a U.S.-based advocacy group, reported that Parkinson's disease is expected to affect 1.3 million individuals by 2030, reflecting a consistent rise in diagnosed cases. Hence, the growing incidence of neurological disorders will significantly contribute to the expansion of the bradykinesia market.

Leading companies in the bradykinesia market are prioritizing the development of innovative solutions, such as sublingual therapies, to provide easier administration for patients who struggle with swallowing pills. Sublingual therapies involve placing the medication under the tongue, allowing it to be quickly absorbed into the bloodstream through the mucous membranes for a rapid therapeutic effect. For example, in March 2023, BIAL, a Portugal-based company specializing in Parkinson's disease treatments, introduced KYNMOBI (apomorphine hydrochloride) for the on-demand management of OFF episodes in Parkinson's disease. These OFF episodes are characterized by the return or worsening of symptoms like bradykinesia, tremor, and rigidity when standard medications lose effectiveness. The sublingual film form of apomorphine hydrochloride provides a fast-acting, easy-to-use option that dissolves beneath the tongue. As a non-ergoline dopamine agonist, it aids in managing sudden motor fluctuations and is generally well-tolerated, offering more consistent control of symptoms during OFF periods.

In October 2023, AbbVie Inc., a U.S.-based biopharmaceutical company, acquired Mitokinin for an undisclosed sum. Post-acquisition, the program gained support from AbbVie's Neuroscience and External Innovation teams, which contributed valuable expertise and resources to advance the initiative toward investigational new drug (IND)-enabling studies. Mitokinin is a U.S.-based company specializing in treatments for bradykinesia.

Major players in the bradykinesia market are AbbVie Inc., Novartis AG, Medtronic Plc, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Lundbeck AS, Amneal Pharmaceuticals Inc., Orion Corporation, Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Denali Therapeutics Inc., Adamas Pharmaceuticals, Impel NeuroPharma, Annovis Bio Inc., BlueRock Therapeutics LLC, NeuroDerm Ltd., Cerevance LLC, Sage Therapeutics, Anavex Life Sciences Corp., Inhibikase Therapeutics Inc.

North America was the largest region in the bradykinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bradykinesia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bradykinesia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bradykinesia market consists of revenues earned by entities by providing services such as motor function assessment, digital monitoring, rehabilitation therapy programs, neurofeedback, and cognitive training. The market value includes the value of related goods sold by the service provider or included within the service offering. The bradykinesia market also includes sales of wearable motion trackers, smart gloves, home-based mobility aids, posture and movement correction devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bradykinesia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bradykinesia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bradykinesia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bradykinesia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Combination Therapy: Mono-Therapy; Combination Therapy
• 2) By Disease Severity: Early-Stage Parkinson's; Advanced-Stage Parkinson's
• 3) By Symptom Management: Bradykinesia; Tremors; Rigidity
• Subsegments:
• 1) By Mono-Therapy: Levodopa; Dopamine Agonists; MAO-B Inhibitors; Anticholinergics; Amantadine
• 2) By Combination Therapy: Levodopa And Carbidopa; Levodopa And COMT Inhibitors; Dopamine Agonists And MAO-B Inhibitors; Levodopa And MAO-B Inhibitors; Triple Therapy
• Companies Mentioned: AbbVie Inc.; Novartis AG; Medtronic Plc; Eli Lilly and Company; Otsuka Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bradykinesia Market Characteristics

3. Bradykinesia Market Trends And Strategies

4. Bradykinesia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bradykinesia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bradykinesia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bradykinesia Market Growth Rate Analysis
• 5.4. Global Bradykinesia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bradykinesia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bradykinesia Total Addressable Market (TAM)

6. Bradykinesia Market Segmentation

• 6.1. Global Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mono-Therapy
• Combination Therapy
• 6.2. Global Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Stage Parkinson's
• Advanced-Stage Parkinson's
• 6.3. Global Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bradykinesia
• Tremors
• Rigidity
• 6.4. Global Bradykinesia Market, Sub-Segmentation Of Mono-Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levodopa
• Dopamine Agonists
• MAO-B Inhibitors
• Anticholinergics
• Amantadine
• 6.5. Global Bradykinesia Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levodopa And Carbidopa
• Levodopa And COMT Inhibitors
• Dopamine Agonists And MAO-B Inhibitors
• Levodopa And MAO-B Inhibitors
• Triple Therapy

7. Bradykinesia Market Regional And Country Analysis

• 7.1. Global Bradykinesia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bradykinesia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bradykinesia Market

• 8.1. Asia-Pacific Bradykinesia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bradykinesia Market

• 9.1. China Bradykinesia Market Overview
• 9.2. China Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bradykinesia Market

• 10.1. India Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bradykinesia Market

• 11.1. Japan Bradykinesia Market Overview
• 11.2. Japan Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bradykinesia Market

• 12.1. Australia Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bradykinesia Market

• 13.1. Indonesia Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bradykinesia Market

• 14.1. South Korea Bradykinesia Market Overview
• 14.2. South Korea Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bradykinesia Market

• 15.1. Western Europe Bradykinesia Market Overview
• 15.2. Western Europe Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bradykinesia Market

• 16.1. UK Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bradykinesia Market

• 17.1. Germany Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bradykinesia Market

• 18.1. France Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bradykinesia Market

• 19.1. Italy Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bradykinesia Market

• 20.1. Spain Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bradykinesia Market

• 21.1. Eastern Europe Bradykinesia Market Overview
• 21.2. Eastern Europe Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bradykinesia Market

• 22.1. Russia Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bradykinesia Market

• 23.1. North America Bradykinesia Market Overview
• 23.2. North America Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bradykinesia Market

• 24.1. USA Bradykinesia Market Overview
• 24.2. USA Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bradykinesia Market

• 25.1. Canada Bradykinesia Market Overview
• 25.2. Canada Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bradykinesia Market

• 26.1. South America Bradykinesia Market Overview
• 26.2. South America Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bradykinesia Market

• 27.1. Brazil Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bradykinesia Market

• 28.1. Middle East Bradykinesia Market Overview
• 28.2. Middle East Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bradykinesia Market

• 29.1. Africa Bradykinesia Market Overview
• 29.2. Africa Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bradykinesia Market Competitive Landscape And Company Profiles

• 30.1. Bradykinesia Market Competitive Landscape
• 30.2. Bradykinesia Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Medtronic Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Bradykinesia Market Other Major And Innovative Companies

• 31.1. Biogen Inc.
• 31.2. Eisai Co. Ltd.
• 31.3. Kyowa Kirin Co. Ltd.
• 31.4. Lundbeck AS
• 31.5. Amneal Pharmaceuticals Inc.
• 31.6. Orion Corporation
• 31.7. Acadia Pharmaceuticals Inc.
• 31.8. Acorda Therapeutics Inc.
• 31.9. Denali Therapeutics Inc.
• 31.10. Adamas Pharmaceuticals
• 31.11. Impel NeuroPharma
• 31.12. Annovis Bio Inc.
• 31.13. BlueRock Therapeutics LLC
• 31.14. NeuroDerm Ltd.
• 31.15. Cerevance LLC

32. Global Bradykinesia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bradykinesia Market

34. Recent Developments In The Bradykinesia Market

35. Bradykinesia Market High Potential Countries, Segments and Strategies

• 35.1 Bradykinesia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bradykinesia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bradykinesia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer